F. Bertheault-Cvitkovic

发表

Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.

T. Conroy, M. Ychou, M. Ducreux, 2005, European journal of cancer.

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

M. Ychou, J. Duffour, M. Ducreux, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma.

F. Lévi, H. Bismuth, J. Misset, 1993, European journal of cancer.

Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients

M. Caterino, F. Lévi, D. Giannarelli, 2000, Anti-cancer drugs.

124 Addition of oxaliplatin (L-OHP®) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advance colorectal cancer (ACC)

F. Lévi, S. Brienza, C. Garufi, 1995 .

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.

F. Lévi, H. Bismuth, J. Misset, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implications of chronobiology for 5-fluorouracil (5-FU) efficacy.

F. Lévi, J. Misset, R. Adam, 1993, Advances in experimental medicine and biology.

A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors

E. Raymond, F. Goldwasser, S. Faivre, 2007, Investigational New Drugs.

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.

F. Lévi, H. Bismuth, S. Giacchetti, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

J. Pierga, V. Diéras, R. Guimbaud, 2005, British Journal of Cancer.

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.

T. Conroy, M. Ychou, J. Douillard, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.

L. Demange, E. Mouret‐Fourme, C. Noguès, 2006, International journal of radiation oncology, biology, physics.

Phase I dose-finding study of BN80927 as an intravenous infusion every 21 days in patients with advanced malignant solid tumors.

T. Lesimple, P. Delavault, G. Prévost, 2010 .

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

V. Diéras, R. Guimbaud, P. Canal, 2005, British Journal of Cancer.